Business briefs: Teva, AbbVie, Novartis, Wockhardt

Share this article:

FDA granted Teva's Plan B One-Step exclusive marketing rights for the next three years. The regulator's ruling made Teva the only company able to sell the drug, in OTC fashion, to all ages. Manufacturers can apply to have their contraceptive sold in drug aisles, but Teva maintains exclusivity to sell their products to those under 17 for three more years.

AbbVie rheumatoid arthritis (RA) drug Humira was shot down by an FDA advisory committee for a potential new indication, treating inflammatory disease of the spine. The committee suggested the drug maker conduct additional trials to prove the drug's efficacy in treating early stages of spondyloarthritis. AbbVie was angling to see Humira approved in spondyloarthritis patients who have been resistant to other treatments.

The Joint Committee on Vaccination and Immunisation (JCVI), a government advisory committee in the UK, rejected Novartis meningitis B vaccine Bexsero, citing a lack of evidence the shot protects children well enough to justify routine use. Prof. David Salisbury, director of immunisation at UK's Department of Health, noted: “This is a very difficult situation, we have a new vaccine against meningitis B but we lack important evidence.” The committee said it plans to give the vaccine to people at high risk of contracting meninigitis B as well as lab workers.

Indian drugmaker Wockhardt was hit with a warning letter from FDA July 18 for concerns about its Waluj plant, in the western part of the country. The generics maker found deficiencies at the plant, which included a lack of drainage from employee urinals. In addition, FDA cited the company for using stall tactics to delay inspection by throwing out paperwork from studies, batch records and stability protocol records.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Genentech shift could prove costly for hospitals

Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies